175 related articles for article (PubMed ID: 24215301)
1. Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
Collin M; Niemann F; Jaisser F
Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoids in the heart and vasculature: new insights for old hormones.
Lother A; Moser M; Bode C; Feldman RD; Hein L
Annu Rev Pharmacol Toxicol; 2015; 55():289-312. PubMed ID: 25251996
[TBL] [Abstract][Full Text] [Related]
3. Targeting the mineralocorticoid receptor in cardiovascular disease.
Young MJ
Expert Opin Ther Targets; 2013 Mar; 17(3):321-31. PubMed ID: 23324064
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.
Piotrowski DW
J Med Chem; 2012 Sep; 55(18):7957-66. PubMed ID: 22866979
[No Abstract] [Full Text] [Related]
5. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology.
Jaisser F; Farman N
Pharmacol Rev; 2016 Jan; 68(1):49-75. PubMed ID: 26668301
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
Bauersachs J; Jaisser F; Toto R
Hypertension; 2015 Feb; 65(2):257-63. PubMed ID: 25368026
[No Abstract] [Full Text] [Related]
7. Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.
Ogawa AK; Bunte EV; Mal R; Lan P; Sun Z; Crespo A; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Jochnowitz N; Ma X; Pan Y; Brown P; Zamlynny B; Bateman T; Leung D; Xu L; Tong X; Liu K; Crook M; Sinclair P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2866-2869. PubMed ID: 27161805
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
Cox JM; Chu HD; Yang C; Shen HC; Wu Z; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2014 Apr; 24(7):1681-4. PubMed ID: 24630411
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
10. [Mineralocorticoid receptor: an update].
Nagase M
Nihon Rinsho; 2012 Sep; 70(9):1504-9. PubMed ID: 23012795
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid Receptor Antagonists.
Nordqvist A; Granberg KL
Vitam Horm; 2019; 109():151-188. PubMed ID: 30678854
[TBL] [Abstract][Full Text] [Related]
12. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
Baxter JD; Funder JW; Apriletti JW; Webb P
Mol Cell Endocrinol; 2004 Mar; 217(1-2):151-65. PubMed ID: 15134814
[TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoid Receptor and Cardiovascular Disease.
Buonafine M; Bonnard B; Jaisser F
Am J Hypertens; 2018 Oct; 31(11):1165-1174. PubMed ID: 30192914
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.
Brem AS; Gong R
Clin Sci (Lond); 2015 May; 128(9):527-35. PubMed ID: 25671776
[TBL] [Abstract][Full Text] [Related]
15. AT1 antagonists: a patent review (2008 - 2012).
Mavromoustakos T; Agelis G; Durdagi S
Expert Opin Ther Pat; 2013 Nov; 23(11):1483-94. PubMed ID: 23968548
[TBL] [Abstract][Full Text] [Related]
16. Role of mineralocorticoid receptor antagonists in cardiovascular disease.
Ferrario CM; Schiffrin EL
Circ Res; 2015 Jan; 116(1):206-13. PubMed ID: 25552697
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor and cardiac arrhythmia.
Gravez B; Tarjus A; Jaisser F
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):910-5. PubMed ID: 23888997
[TBL] [Abstract][Full Text] [Related]
19. The aldosterone receptor--new insights?
Fuller P
Expert Opin Investig Drugs; 2006 Mar; 15(3):201-3. PubMed ID: 16503757
[TBL] [Abstract][Full Text] [Related]
20. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
Davel AP; Jaffe IZ; Tostes RC; Jaisser F; Belin de Chantemèle EJ
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H989-H999. PubMed ID: 29957022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
